652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)
| Autor: | Toh, H.C., Yang, M-H., Wang, H-M., Hsieh, C-Y., Chitapanarux, I., Ho, K.F., Hong, R-L., Ang, M-K., Colevas, D., Sirachainan, E., Lertbutsayanukul, C., Ho, G.F., Samol, J., Huang, Z., Tan, C., Ding, C., Myo, A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S840-S840 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|